What is the recommended treatment approach for ulcerative colitis, including induction and maintenance therapy?

Treatment of Ulcerative Colitis

For mild-to-moderate ulcerative colitis, start with high-dose oral 5-ASA (mesalamine 2.4-4.8 g/day) combined with rectal 5-ASA therapy, and escalate to oral prednisolone 40 mg daily if no response within 2-4 weeks; for moderate-to-severe disease, use advanced therapies (infliximab, vedolizumab, upadacitinib, or ustekinumab) as first-line treatment, with upadacitinib showing the highest efficacy in recent trials. 1, 2, 3, 4

Disease Severity Stratification

Treatment selection depends critically on disease severity and extent:

• Mild-to-moderate disease: Defined by ambulatory status with <4 bloody stools daily, no systemic toxicity, and normal inflammatory markers 5, 6
• Moderate-to-severe disease: Defined by ≥6 bloody stools daily with evidence of systemic toxicity (fever, tachycardia, anemia, elevated ESR >30 mm/hr) 1, 2
• Acute severe colitis: Requires hospitalization with ≥6 bloody stools daily plus systemic toxicity, representing a medical emergency with 25-30% colectomy risk 7, 2

Mild-to-Moderate Disease: Induction Therapy

First-Line Treatment by Disease Extent

For ulcerative proctitis (disease <15-20 cm from anus):

• Mesalamine suppositories 1 g daily as first-line therapy 5, 6
• If suppositories fail or are not tolerated, add oral 5-ASA 2-3 g/day or switch to rectal corticosteroid foam 5, 8

For left-sided colitis (disease to splenic flexure):

• Mesalamine enemas ≥1 g daily combined with oral 5-ASA 2.4-4.8 g/day 9, 5, 6
• This combination is superior to oral therapy alone for inducing remission 9, 6

For extensive colitis (disease beyond splenic flexure):

• High-dose oral 5-ASA 2.4-4.8 g/day as minimum effective dose 9, 6
• Add rectal 5-ASA therapy for faster and more complete remission 9, 6
• Once-daily dosing is acceptable and may improve adherence compared to divided dosing 9, 5

Escalation for 5-ASA Failure

Evaluate treatment response at 2-4 weeks; if inadequate response:

• Initiate oral prednisolone 40 mg daily, tapering over 6-8 weeks 2, 5, 10
• Alternative: Budesonide MMX 9 mg daily for patients prioritizing avoidance of systemic corticosteroid effects, though slightly less effective than prednisolone 2, 10

Critical pitfall: Never use corticosteroids for maintenance therapy—they are for induction only 5, 10

Escalate to advanced therapy if:

• No adequate response to oral corticosteroids within 2 weeks 2
• Corticosteroid-dependent (unable to taper without relapse) 10, 6
• Requiring ≥2 corticosteroid courses per year 10, 6

Moderate-to-Severe Disease: Advanced Therapies

Biologic-Naive Patients

The 2024 AGA guideline stratifies advanced therapies by efficacy tier 3:

HIGHER efficacy medications (choose from these first):

• Infliximab 1, 3
• Vedolizumab 1, 3
• Upadacitinib 3, 4
• Risankizumab 3
• Guselkumab 3
• Ozanimod 3
• Etrasimod 3

INTERMEDIATE efficacy medications:

• Golimumab 1, 3
• Ustekinumab 1, 3
• Tofacitinib 1, 3
• Filgotinib 3
• Mirikizumab 3

LOWER efficacy medications (avoid as first choice):

• Adalimumab 1, 3

Specific Efficacy Data

Upadacitinib demonstrates the highest efficacy in recent head-to-head network meta-analyses:

• Induction remission: 26-34% vs 3-8% placebo (RR 7.15,95% CI 4.26-11.99) 3, 4
• Maintenance remission at 52 weeks: 42% (15 mg twice daily) to 52% (30 mg twice daily) vs 12% placebo 3, 4
• Intent-to-treat efficacy rates highest across all outcomes regardless of prior biologic exposure 11, 4

For biologic-naive patients, the 2020 AGA guideline suggests:

• Infliximab or vedolizumab over adalimumab for induction (conditional recommendation) 1
• Patients valuing convenience of subcutaneous self-injection may reasonably choose adalimumab despite lower efficacy 1

JAK Inhibitor Considerations

FDA labeling restricts JAK inhibitors to second-line use:

• Tofacitinib and upadacitinib should only be used after failure of or intolerance to TNF antagonists per FDA guidance 1, 3
• Use in biologic-naive patients should occur only in clinical trials or registry studies 1

Tofacitinib dosing specifics:

• Induction: 10 mg twice daily for 8 weeks (may extend to 16 weeks in partial responders) 1
• Maintenance: 5 mg twice daily for most patients 1, 12
• Higher maintenance dose (10 mg twice daily) may be needed in some patients but carries increased risk of pulmonary embolism and all-cause mortality 1, 12
• Herpes zoster vaccination recommended before initiation 2

Upadacitinib dosing:

• Induction: 45 mg once daily for 8 weeks 3, 4
• Maintenance: 15 mg or 30 mg once daily 3, 4
• 30 mg maintenance dose shows higher remission rates (52% vs 42% for 15 mg) but requires careful risk-benefit assessment 4

Biologic-Exposed Patients

All advanced therapies remain effective after TNF antagonist failure, though with reduced efficacy:

• Infliximab: RR 2.85 (95% CI 2.11-3.86) for induction 1
• Vedolizumab: RR 2.22 (95% CI 1.36-3.64) for induction 1
• Ustekinumab: RR 2.91 (95% CI 1.72-4.94) for induction 1
• Tofacitinib: RR 3.22 (95% CI 2.03-5.08) for induction 1

Switching within drug class: Switching from one TNF antagonist to another TNF antagonist is reasonable after secondary loss of response 1

Maintenance Therapy

Continue the agent that successfully induced remission for long-term maintenance 2, 5:

5-ASA maintenance:

• Minimum 2 g/day oral 5-ASA for extensive disease 5, 10, 6
• Continue rectal 5-ASA if used for induction of left-sided disease or proctitis 5, 6
• Lifelong maintenance recommended for all patients, especially those with left-sided or extensive disease 7

Advanced therapy maintenance:

• Infliximab: Continue at induction dose and interval (typically 5 mg/kg every 8 weeks) 1
• Vedolizumab: 300 mg every 8 weeks 1
• Ustekinumab: 90 mg subcutaneously every 8-12 weeks 1
• Tofacitinib: 5 mg twice daily (10 mg twice daily if loss of response on lower dose) 1, 12
• Upadacitinib: 15 mg or 30 mg once daily 3, 4

Thiopurine monotherapy:

• Azathioprine or mercaptopurine can maintain remission but typically require corticosteroid induction first 7, 2
• Consider as steroid-sparing maintenance in patients who cannot access or tolerate biologics 7, 10

Acute Severe Colitis (Hospitalized Patients)

Immediate management upon admission:

• Intravenous corticosteroids: hydrocortisone 400 mg/day or methylprednisolone 60 mg/day 7, 2
• Assess response at 3 days using clinical parameters and biomarkers 2, 13
• Joint management with gastroenterology and colorectal surgery from admission 7, 2

For corticosteroid-refractory disease (no improvement by day 3-5):

• Infliximab 5 mg/kg intravenous (standard dosing) or intensified dosing regimens 1, 14, 13
• Cyclosporine 2 mg/kg/day intravenous (alternative to infliximab) 7, 14
• JAK inhibitors show promise but evidence remains preliminary 13

Supportive care essentials:

• Intravenous fluid and electrolyte replacement 7
• Blood transfusion to maintain hemoglobin >10 g/dL 7
• Subcutaneous heparin for thromboembolism prophylaxis 7
• Daily abdominal radiography if colonic dilatation present (transverse colon >5.5 cm) 7
• Nutritional support if malnourished 7

Colectomy indicated if:

• No response to medical rescue therapy within 7 days 7, 2
• Clinical deterioration with toxic megacolon, perforation, or uncontrolled bleeding 7, 2
• Approximately 20% of patients require colectomy within 5 years of diagnosis 15

Treatment Goals and Monitoring

Target treat-to-target endpoints:

• Clinical remission (≤1 formed stool daily without blood) 2, 5
• Biochemical remission (fecal calprotectin normalization) 2, 15
• Endoscopic remission (Mayo endoscopic subscore 0-1) 2
• Histologic remission (absence of neutrophils in lamina propria) 2

Monitoring schedule:

• Assess clinical response to 5-ASA at 4-8 weeks 5, 6
• Assess response to corticosteroids at 2 weeks 2, 10
• Colonoscopy at 8 years from diagnosis for dysplasia surveillance, then every 1-3 years depending on risk factors 15
• Renal function monitoring for patients on long-term 5-ASA: baseline, 2-3 months, then annually 10

Common Pitfalls to Avoid

Do not:

• Use corticosteroids for maintenance therapy (high relapse rate and toxicity) 5, 10
• Switch between different oral 5-ASA formulations in patients who failed one formulation (no evidence of benefit) 5
• Delay escalation to advanced therapy in patients requiring repeated corticosteroid courses 10, 6
• Use JAK inhibitors as first-line therapy in biologic-naive patients outside clinical trials (FDA restriction) 1, 3
• Continue 5-ASA monotherapy in patients with high-risk features (extensive disease, young age at diagnosis, severe endoscopic inflammation) without close monitoring 6

Alternative and Adjunctive Therapies

The AGA makes no recommendation for use outside clinical trials:

• Probiotics 6, 8
• Curcumin 6, 8
• Fecal microbiota transplantation 9, 6, 8

These unproven therapies may delay effective treatment and increase risk of complications 8